The fatty liver illness MASH is without doubt one of the metabolic problems that Nula Therapeutics is pursuing. The startup’s small molecules are meant to revive the integrity of the nuclear envelope, a mobile membrane whose dysfunction can contribute to metabolic illness.
The submit Startup Nula Emerges to Advance a New Class of Medicines for Metabolic Illness appeared first on MedCity Information.
